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Abstract
Cholangiocarcinoma, also known as bile duct cancer, is the second most common primary hepatic carcinoma with a median
survival of less than 2 years. The molecular mechanisms underlying the development of this disease are not clear. To survey
activated tyrosine kinases signaling in cholangiocarcinoma, we employed immunoaffinity profiling coupled to mass
spectrometry and identified DDR1, EPHA2, EGFR, and ROS tyrosine kinases, along with over 1,000 tyrosine phosphorylation
sites from about 750 different proteins in primary cholangiocarcinoma patients. Furthermore, we confirmed the presence of
ROS kinase fusions in 8.7% (2 out of 23) of cholangiocarcinoma patients. Expression of the ROS fusions in 3T3 cells confers
transforming ability both in vitro and in vivo, and is responsive to its kinase inhibitor. Our data demonstrate that ROS kinase
is a promising candidate for a therapeutic target and for a diagnostic molecular marker in cholangiocarcinoma. The
identification of ROS tyrosine kinase fusions in cholangiocarcinoma, along with the presence of other ROS kinase fusions in
lung cancer and glioblastoma, suggests that a more broadly based screen for activated ROS kinase in cancer is warranted.
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Introduction
Despite major efforts to improve diagnosis and treatment of liver
cancer, the five-year survival rate of individuals with this disease is
very poor, marking this malignancy as one of the most lethal
cancers[1]. Primary liver cancer comprises histologically distinct
hepatic neoplasms. The two most common types of liver cancer are
hepatocellular carcinoma (HCC), accounting for 80% of all cases,
and cholangiocarcinoma (CCA, or bile duct cancer), representing
10–15%of hepatobiliary neoplasms [2,3]. While chronic hepatitis B
and C infection, alcohol consumption, and toxins are risk factors
associated with HCC, little is known about the molecular
pathogenesis of cholangiocarcinoma[4]. There are over 90
annotated tyrosine kinases in the human genome that are important
regulators of intracellular signal transduction pathways mediating
cellular proliferation, survival, and development [5]. The activity of
these kinases is normally tightly regulated, and constitutive
activation of tyrosine kinases by acquired somatic mutation
contributes to oncogenic transformation in many cancers [6].
To facilitate the identification of tyrosine kinases and phos-
phorylation events involved in the pathogenesis of cholangiocarci-
noma, we applied a strategy based on immunoaffinity purification
of tyrosine phosphorylated peptides followed by LC-MS/MS
based identification [7,8,9]. Using this phosphoproteomic ap-
proach, we broadly surveyed tyrosine kinase signaling in primary
cholangiocarcinomas, and identified activated ROS kinase not
previously known to play a role in cholangiocarcinoma. Upon
further biochemical and functional analysis, we confirmed the
oncogenic property of ROS kinase fusions. This is the first report
of chromosomal translocation involving a tyrosine kinase in
cholangiocarcinoma, and provides new insights into signaling
pathways and therapeutic targets in this disease.
Results
Profiling of phosphotyrosine signaling in
cholangiocarcinoma by LC-MS/MS mass spectrometry
To survey protein tyrosine phosphorylation in cholangiocarci-
noma (CCA), we applied an immunoaffinity phosphoproteomic
approach [9]. Resected primary CCA were homogenized and
digested with trypsin, phosphopeptides were immunoprecipitated
with phosphotyrosine antibody (pY-100), and analyzed by LC-
MS/MS mass spectrometry [8,9]. Matching para-tumor tissues of
similar size were also included in the study. Table S1 shows
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15640phosphotyrosine profiles from 23 primary CCA and 20 para-
tumor tissues. About 1053 tyrosine phosphorylation sites were
identified on 746 different proteins by high resolution, high
accuracy MS, with the global false positive rate to be less than
5.0%. This study significantly extended our knowledge of tyrosine
kinase signaling in cholangiocarcinoma, and these data have been
deposited in PhosphoSitePlus
TM (www.phosphosite.org), a freely
accessible database for phosphorylation and other posttranslation-
al modifications. First, we compared the receptor tyrosine kinase
(RTK) phosphorylation profile between tumors and para-tumor
tissues. While tumors show high levels of DDR1, EphA2, EGFR,
and ROS1 tyrosine kinase phosphorylation, para-tumor tissues
showed the highest level of tyrosine phosphorylation in EGFR,
AXL, EPHB4, and PDGFRA. Of note, we also observed the
presence of MET kinase activity in para-tumor tissues, consistent
with the requirement of EGFR and hepatocyte growth factor/c-
met signaling pathways for normal hepatocyte development, as
well as liver regeneration [10,11] (Figure 1A). On the other hand,
PTK2 (FAK) and SRC-family kinases make up the majority of
cytoplasmic tyrosine kinase (CTK) phosphorylation in these two
groups (Figure 1B).
Cholangiocarcinoma is a heterogeneous disease, individual
patient may have distinct tyrosine kinase profile. To identify
aberrant receptor tyrosine kinases (RTKs) signals in individual
CCA, the number of phosphopeptides per RTK was normalized
against total number of phosphopeptides of GSK3A (100) from
each sample (Table S2)[8], then average RTK signals from 20
para-tumor tissues were subtracted from each CCA tumor
(N=23). Unsupervised hierarchical clustering revealed the
presence of two groups, tumors expressing little or no RTKs
activity (group 1, N1=5, 22%), and tumors expressing kinases,
such as DDR1, EPHA2, and ROS1 (group 2, N2=18, 78%)
Figure 1. Identification of aberrantly phosphorylated tyrosine kinases in cholangiocarcinoma. (A) and (B) Distribution of receptor
tyrosine kinases (RTKs) and non-receptor tyrosine kinases (CTKs) in tumors and matching para-tumor tissues. The total number of spectral counts of
each RTK/CTK is normalized against total number of phosphopeptides of GSK3A (100) in each sample, then the sum of the normalized number of
each RTK/CTK as fractions of the total are shown. See Table S2. (C) Receptor tyrosine kinase (RTK) profiles from 23 CCA samples revealed
heterogeneous tyrosine kinase activities in CCA. Average RTK signals from 20 normalized para-tumor tissues were subtracted from each CCA sample.
The yellow color represents kinases aberrantly phosphorylated in CCA, and the blue color represents kinases under phosphorylated in tumor. ‘TC’ for
cholangiocarcinoma tumor samples. (D) Ranking of RTK phosphorylation in CCA. Phospho level/sample was derived from average of normalized
phosphopeptide spectra of each RTK from tumor samples showing positive signal of this RTK. (E) Distribution of RTKs in two cholangiocarcinoma
samples (TC03 and TC23). RTK values were presented as fractions of the total RTK values from each sample.
doi:10.1371/journal.pone.0015640.g001
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activities in CCA, we applied a ranking method developed by
Rikova et al [8]. As shown in Figure 1D, ROS1, DDR1, and
EPHA2 are the top ranked kinases identified in CCA. Further-
more, phosphopeptides from ROS kinase were identified in two
tumors (TC03 and TC23), but not in the corresponding para-
tumor tissues (Table S1, NC23 and NC03), and presented as the
major tyrosine kinase activities in these two samples (Figure 1E).
DNA sequencing analysis did not detect any mutations in the
kinase domains of ROS (data not shown). While the full length
ROS protein has a molecular weight of 258 kDa, a truncated form
of ROS protein (60–80 kDa) was detected by Western blot analysis
from one of the ROS positive primary tumor (TC23) (Figure S1A).
To elucidate the molecular mechanisms leading to truncation and
activation of ROS kinase in CCA, we performed 59 rapid
amplification of cDNA ends (59 RACE) on RNA from two ROS
positive patient samples. Sequence analysis of the resulting product
showed that the kinase domain of ROS was fused in-frame to the
Fused in Glioblastoma (FIG) gene. Two different forms of FIG-
ROS fusion were identified (Figure 2A). In sample TC23, exon 3
of FIG was fused to exon 36 of ROS. The fusion protein, named
FIG-ROS(S), combines the amino terminal 209 amino acids of
FIG with the carboxyl terminal 421 amino acids of ROS. In
sample TC03, exon 7 of FIG was fused to exon 35 of ROS. The
fusion protein, FIG-ROS(L), combines the first 412 amino acids of
FIG with the carboxyl terminal 466 amino acids of ROS. It is the
same FIG-ROS fusion protein previously identified in a
glioblastoma cell line U118MG, representing the first case of the
same tyrosine kinase fusion involved in two distinct types of
cancer. FIG (GOPC), a PDZ domain containing Golgi protein,
plays an important role in intracellular protein trafficking and
degradation [12]. Meanwhile, ROS tyrosine kinase is an orphan
receptor whose normal expression pattern is tightly spatio-
temporally regulated during development [13]. While we did not
detect the expression of wild type ROS gene, expression of FIG
gene was confirmed in these two samples (Figure 2B), suggesting
that expression of FIG-ROS fusion gene contributes to the
tyrosine phosphorylation of ROS kinase. U118MG cells, which
are known to have homozygous deletion at 6q21 [14], did not
express either wild type FIG or ROS gene. HCC78, a non-small
cell lung cancer cell line, which contains SLC34A2-ROS fusion
[8], expresses both FIG and ROS gene. The fusion product of FIG
and ROS was further confirmed by reverse-transcriptase-PCR
(Figure 2C). In addition, we did not detect any FIG-ROS fusions
in over 60 hepatocellular carcinoma samples (data not shown).
Moreover, genomic PCR was performed to identify the genomic
breakpoint for each patient (Figure 2D and Figure S1B). Attempts
to amplify the reciprocal fusion genes were unsuccessful (data not
shown), indicating that all fusions were the result of a deletion on
6q21 and not of t(6;6). Thus, we identified 2 patients with ROS
kinase fusions in 23 CCA, with a frequency of 8.7%.
FIG-ROS fusions transform NIH3T3 cells both in vitro and
in vivo
While FIG-ROS(L) was previously reported to be oncogenic
both in vitro and in vivo [14,15], not much is known about the
transforming ability of FIG-ROS(S). To this end, we transfected
3T3 cells with retroviral constructs (C- terminal Myc-Tag)
containing FIG-ROS(S), FIG-ROS(L), and SLC34A2-ROS(S),
respectively. SLC34A2-ROS(S) was the short form of ROS fusion
previously identified in NSCLC [8]. pMSCV vector lacking any
ROS fusion cDNA was used as a negative control (Figure 3A).
48 hours after transfection, 3T3 cells were selected for neomycin
resistance for 7 days. Western blot analysis showed that both forms
of FIG-ROS fusions activate known downstream effectors of ROS,
such as STAT3 and AKT (Figure S2A). On the other hand,
SLC34A2-ROS(S) has minimal effects on STAT3 and AKT in
this system (Figure S2B). To determine whether FIG-ROS(S) can
cause anchorage-independent growth of 3T3 cells, stably trans-
fected 3T3 cells were cultured in soft agar for 17 days. As shown in
Figure 3B (top panel), FIG-ROS(S) expressing 3T3 cells formed
large number of colonies in soft agar, whereas none were observed
in the negative control, indicating that FIG-ROS(S) can transform
3T3 cells in vitro. Meanwhile, the presence of either FIG-ROS(L)
or SLC34A2-ROS(S) also enabled 3T3 cells to form colonies,
although the effect was not as significant as that seen with FIG-
ROS(S). Thus, it is possible that that FIG-ROS(S) might be a more
potent kinase than FIG-ROS(L). To further investigate the
transforming ability of FIG-ROS(S) in vivo, Immunocompromised
nude mice were injected with 1610
6 3T3 cells transduced with
retrovirus containing empty vector, FIG-ROS(S), FIG-ROS(L), or
SLC34A2-ROS(S). Mice were monitored daily for tumor forma-
tion and size, and were sacrificed when tumors reached approxi-
mately 1 cm61 cm. As shown in Figure 3B (bottom panel), two
weeks after being injected with 3T3 cells transduced with either
FIG-ROS(S), FIG-ROS(L) or SLC34A2-ROS(S), tumor forma-
tion was apparent in all the injected nude mice. In contrast,
tumors were not found in mice injected with pMSCV vector
control 3T3. Thus, we confirmed that, like FIG-ROS(L), FIG-
ROS(S) is tumorgenic both in vitro and in vivo.
The transforming ability of FIG-ROS(L) requires targeting to
the Golgi apparatus through the second coiled-coil domain of FIG
[16]. To ascertain the subcellular localization of FIG-ROS(S), we
performed immunofluorescence assay with 3T3 cells stably
transfected with the ROS fusion variants with Myc-tag antibody.
As expected, FIG-ROS(L) targets to the Golgi apparatus, and co-
localizes with the Golgi marker (golgin-97). To our surprise, the
staining pattern of FIG-ROS(S) was cytoplasm, even though it
contains the second coiled-coil domain of FIG (Figure 3C),
suggesting that the coiled-coil domain of FIG is necessary, but not
sufficient to target FIG-ROS(S) to the Golgi apparatus. Interest-
ingly, SLC34A2-ROS(S) was localized to para-nuclei compart-
ment. These results were further confirmed by a ROS antibody
(Figure 3D). Thus, different ROS fusions have distinct subcellular
localization, suggesting that they may activate different substrates
in vivo.
FIG-ROS fusion is a potential therapeutic target
The oncogenecity of FIG-ROS fusions were further evaluated
by their abilities to transform interleukin-3 (IL-3)-dependent
murine lymphoid BaF3 cells to cytokine-independent growth.
Retroviral transduction of either FIG-ROS(S) or FIG-ROS(L)
transformed BaF3 cells to factor independent growth (Figure 4A
and Figure S2C), and there is a shorter latency for FIG-ROS(S) to
transform BaF3 cells than seen with FIG-ROS(L), indicating that
FIG-ROS(S) might be a more potent kinase than FIG-ROS(L) as
suggested by previous soft agar assay. To confirm this finding, we
performed in vitro kinase assay. While both forms of FIG-ROS
fusions showed increased tyrosine kinase activity in vitro as
compared to control, FIG-ROS(S) has more than 4 fold higher
kinase activity than FIG-ROS(L) (Figure S2D). Since ROS kinase
shares high sequence homology with ALK, we evaluated the
potential of TAE684 (an ALK inhibitor) to inhibit ROS kinase
activity and signaling. Treatment of TAE684 abolished the growth
of BaF3 cells expressing either FIG-ROS(S) or FIG-ROS(L) with
IC50 of 10 nM and 1.8 nM, respectively (Figure 4B). As expected,
NPM-ALK expressing Karpas-299 is sensitive to TAE684 with an
IC50 of 4.8 nM, similar to the IC50 previously reported [17]. On
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TAE684, neither did BaF3 cells expressing empty vector (Neo-
Myc). These data confirm that FIG-ROS is the target of TAE684.
To understand the biological effects of inhibition of FIG-ROS on
the growth and survival of BaF3 cell lines, we performed apoptosis
analysis on cells treated with either TAE684 or DMSO. BaF3
Figure 2. Identification of ROS kinase fusions in CCA patients. (A) Schematic diagram shows the Fused in Glioblastoma (FIG), ROS and FIG-ROS
proteins. The position of the breakpoint is indicated by arrowhead (red or black). PDZ stands for PDZ domain, a protein-interaction domain; TM for
transmembrane. Blue boxes refer to the two coiled-coil domains. The amino acid and DNA sequence from junction of the ROS fusions are listed. FIG-ROS (L)
and FIG-ROS (S) refer to the long form and the short form of ROS fusions, respectively. (B) Expression of FIG and ROS mRNA in FIG-ROS positive
cholangiocarcinoma patients. a. primer pairs FIG-F2 and ROS-GSP3.1 for FIG-ROS. b. primer pairs ROS-Ex31F and ROS-GSP2 for ROS. c. primer pairs FIG-F3 and
FIG-R8 for FIG. U118MG and HCC78 were used as controls. (C) RT-PCR reaction identified a fusion of FIG to ROS in cDNA from two cholangiocarcinoma patients.
GAPDH was used as a control. cDNA from U118MG cell line was included as a positive control. ‘C’ for cholangiocarcinoma, and ‘H’ for hepatocellular carcinoma.
(D) Genomic breakpoints of FIG and ROS fusion gene for each patient. FIG intron sequences are shown in blue, and ROS intron sequences are shown in red or
black. For TC23, the intron sequences between FIG-ROS fusion gene are composed of 1–822 base pair (bp) from intron 3 of FIG, antiparallel sequence of 620–
656 bp derived from intron 35 of ROS (shown in red), and 666–1228 bp from intron 35 of ROS. For TC03, the intron sequences between FIG-ROS fusion gene
consist of 1–2402 bp from intron 7 of FIG and 2317–2937 bp from intron 34 of ROS. Splice donor acceptor sites are shown in Italics.
doi:10.1371/journal.pone.0015640.g002
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PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e15640Figure 3. Characterization of FIG-ROS fusions. (A) Schematic representations of FIG-ROS used in the study. MSCV denotes murine stem cell
virus; Neo for Neomycin; LTR for long terminal repeat; Green box for Myc-Tag. (B) Expression vectors for FIG-ROS(S), FIG-ROS(L), and SLC34A2-ROS(S)
(or the corresponding empty vector) were introduced into 3T3 cells. Triplicate experiments were performed. The cells from representative experiment
were photographed after 17 days of culture (upper panels). The same set of transfected cells was also injected subcutaneously at 2 sites into each
nude mice, and tumor formation was examined after 16 days (lower panels). The number of tumors formed after eight injections are indicated.
(C) and (D) ROS fusions display distinct subcellular localization. Shown is indirect immunofluorescence analysis of clonally derived 3T3 cells
expressing FIG-ROS(S), FIG-ROS(L), SLC34A2-ROS(S) (or the corresponding empty vector). Cells were fixed and stained with Myc-Tag, Golgin-97(Golgi
marker), and ROS antibody. Nuclei are stained with DAPI (blue).
doi:10.1371/journal.pone.0015640.g003
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299 cells were treated with 100 nM of TAE684 for 48 h and were
assessed for induction of apoptosis by flow cytometry analysis. At
48 h after incubation with TAE684, 85–95% of FIG-ROS
expressing cells stained positive for cleaved caspase 3 in several
independent experiments. In contrast, no increase in the number
of cleaved caspase-positive cells was seen in BaF3 cells expressing
FLT3-ITD (Figure 4C). Although karpas-299 did not undergo
significant apoptosis when treated with TAE684, it was primarily
due to cell cycle arrest (data not shown) [17]. To find out whether
TAE684 also inhibits signaling downstream of FIG-ROS, FIG-
ROS expressing BaF3 cells were treated with either DMSO or
increasing concentrations of TAE684 for 3 hours. As demonstrat-
ed in Figure 4D, TAE684 inhibited ROS phosphorylation in a
dose dependent manner. The impact of FIG-ROS inhibition on its
downstream signaling was evaluated by using p-STAT3, p-AKT,
p-ERK, and p-Shp2 as surrogate markers for JAK/STAT, PI3K-
AKT, RAS/MAPK pathways. Clearly, inhibition of FIG-ROS by
TAE684 led to a dose-dependent reduction in phosphorylation of
STA3, AKT, ERK, and Shp2 in BaF3 cells. As expected, we
observed inhibition of ALK downstream signaling molecules in
Karpas-299 cells upon treatment of TAE684. In contrast, we do
not see significant changes in the phosphorylation of FLT3 and its
downstream signaling intermediates. These results demonstrate
that TAE684 inhibits not only FIG-ROS, but also its crucial
downstream signaling molecules.
Discussion
In this study, we surveyed tyrosine kinase signaling events in
cholangiocarcinoma using an unbiased phosphoproteomic ap-
proach. This approach is a sensitive and reproducible functional
strategy to identify activated protein kinases and their phosphor-
ylated substrates without prior knowledge of the signaling
networks [7,8]. Furthermore, in the context where protein tyrosine
kinases are known to play an important role in many human
cancer genes [6,18], phosphoproteomic analysis provides a
functional screening assay to rapidly identify constitutively
activated tyrosine kinases regardless of the molecular mechanism
of activation. This analysis generated a deep and broad view of
tyrosine kinase activity and downstream signaling networks that
were not revealed before.
By following up tyrosine kinase profile in individual patient, we
identified activated ROS kinase in cholangiocarcinoma. Elevated
Figure 4. Transformation, inhibition, and signaling properties of the FIG-ROS fusion tyrosine kinase. (A) BaF3 cells retrovirally
transduced with ROS fusion constructs were grown in the absence of IL-3. (B) Dose response graph of TAE684 for BaF3 cells expressing FIG-ROS
fusions. BaF3/FLT3-ITD, and Karpas-299 (NPM-ALK) cells were used as controls. Triplicate experiments were performed. (C) Treatment with TAE684
increased apoptosis of BaF3 cells expressing FIG-ROS fusions, but not FLT3-ITD as measured by cleaved caspase-3 staining. Representative results
from triplicate experiments were included. (D) Incubation with different concentrations of TAE684 resulted in decreased phosphorylation of ROS
kinase, accompanied by decreased phosphorylation of STAT3, AKT, ERK, and Shp-2.
doi:10.1371/journal.pone.0015640.g004
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(NSCLC) and breast cancer [19,20,21]. Demethylation of ROS
promoter contributes to the elevated expression of ROS kinase in
malignant gliomas [22]. Chromosomal rearrangements involving
ROS kinase have been reported in glioblastoma and non-small cell
lung cancer [8,14]. Since expression of FIG-ROS in CNS induces
glioblastoma formation in vivo [15], we speculate that expression of
FIG-ROS could develop cholangiocarcinoma in vivo as well.
In the present study, we identified aberrant ROS kinase expre-
ssion in 8.7% cholangiocarcinoma patients. Cholangiocarcinoma
is the second most common primary hepatic carcinoma. Advanced
cholangiocarcinoma has a median survival of less than 2 years.
While the only curative therapy is surgical extirpation or liver
transplantation, most patients with cholangiocarcinoma present
with advanced stage disease, which is not suitable for surgery [2,3].
Our data suggest that inhibition of the tyrosine kinase activity of
ROS may induce growth inhibition and cell death in BaF3 cells
expressing this fusion protein. Thus, specific ROS inhibitors may
provide means to treat patients with liver cancer that expresses
ROS fusions, for whom effective treatments are rarely available.
Since attempts to identify cholangiocarcinoma cell lines containing
FIG-ROS fusions were unsuccessful, these FIG-ROS transformed
BaF3 cell lines could be used as in vitro models to screen ROS
inhibitors. Given that the association of FIG-ROS with both
cholangiocarcinoma and glioblastoma, it will be important to
examine the association of FIG-ROS and other activated ROS
alleles with other types of cancers, as well as in other ethnic groups.
By integrating genetic, epigenetic, proteomic, and phosphopro-
teomic information, we can begin to understand the pathogenesis
of cholangiocarcinoma and identify novel therapeutic targets.
Materials and Methods
Cell lines and tumors
BaF3 and Karpas-299 cells were obtained from DSMZ
(Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH, Germany). U118 MG, HCC78, and 3T3 cells were
purchased from American Type Culture Collection (Manassas,
VA). BaF3 cells were maintained in RPMI-1640 medium
(Invitrogen) with 10% fetal bovine serum (FBS) (Sigma) and
1.0 ng/ml IL-3 (R&D Systems). Karpas-299 cells were grown in
RPMI-1640 with 10% FBS. Other cell lines were grown in
DMEM with 10% FBS.
Cholangiocarcinoma tumors (n=23), as well as matching para-
tumor tissues (n=20) were collected within 15 minutes from
surgical resections from patients when sufficient material for
PhosphoScanH analysis, RNA, and DNA extractions were
available. According to the Edmondson grading system, all tumor
samples have differentiation grades II–III. The tumor specimens
were collected at RuiJin hospital (Shanghai, China) and Third
Xiangya hospital (Changsha, Hunan, China) with written consent
from patients. Patient information was not revealed in this study,
and the data were analyzed anonymously. Obtaining patient
materials were approved by both Ruijin hospital and third
Xiangya hospital institutional review board.
Phosphopeptide immunoprecipitation and analysis by
LC-MS/MS Mass Spectrometry
Phosphopeptides were prepared using PhosphoScanH Kit (Cell
Signaling Technology). In brief, about 200–500 mg tumor samples
were homogenized and lysed in urea buffer, trypsin digested lysates
were purified by Sep-pak C18 column (Waters). Then, lyophilized
peptides were redissolved and immunoaffinity purified with pY-100
antibody. pTyr-containing peptides were concentrated on reverse-
phase micro tips. LC-MS/MS analysis was performed with an LTQ
Orbitrap Mass Spectrometer (Thermo Fisher Scientific) and a peptide
mass accuracy of 63 ppm was one of the filters used for peptide
identification. Details were described previously [8]. In brief, samples
were collected with an LTQ – Orbitrap hybrid mass spectrometer,
using a top-ten method, a dynamic exclusion repeat count of 1, and a
repeat duration of 30 sec. MS spectra were collected in the Orbitrap
component of the mass spectrometer and MS/MS spectra was
collected in the LTQ. Sequest (Thermo Fisher Scientific) searches were
done against the NCBI human database released on July 02, 2009,
(containing 37,391 proteins), allowing for tyrosine phosphorylation
(Y+80) and oxidized methionine (M+16) as differential modifications.
The PeptideProphet probability threshold was chosen to give a false
positive rate of 5% for the peptide identifications[23].
Clustering analysis
For each patient sample, each protein’s spectral counts were
normalized to those for GSK3A (100). We used the following
statistical and computational tools from GenePattern 3.0 software
package (Broad Institute of MIT and Harvard) for Comparative
Marker Selection; from MultiExperiment Viewer version 4.4 for
Hierarchical Clustering (Pearson correlation distance and com-
plete linkage clustering).
Rapid Amplification of Complementary DNA Ends
RNeasy Mini Kit (Qiagen) was used to extract RNA from
human tumor samples. DNA was extracted with the use of
DNeasy Tissue Kit (Qiagen). Rapid amplification of cDNA ends
was performed with the use of 59 RACE system (Invitrogen) with
primers ROS-GSP1 for cDNA synthesis and ROS-GSP2 and
ROS-GSP3.1 for a nested PCR reaction, followed by cloning and
sequencing PCR products.
Transfection, cell proliferation and growth assays
Transfections were carried out using FuGENE 6 (Roche
Diagnostics), and retrovirus was harvested at 48 after transfection.
BaF3 cells were transduced with retroviral supernatant containing
either the MSCV-Neo/FIG-ROS(L) or MSCV-Neo/FIG-ROS(S)
vector, and selected for G418 (0.8 mg/ml). IL-3 independent
growth was accessed by plating transduced BaF3 cells in IL-3 free
medium, after the cells were washed three times in PBS. For dose
response curves, cells were incubated for 72 hours in the presence
of TAE684 (customer synthesized), and the number of viable cells
was determined with the CellTiter 96 AQueous One solution cell
proliferation assay (Promega). IC50 was calculated with the use of
OriginPro 6.1 software (OriginLab). The percentage of apoptotic
cells at 48 hours was determined by flow cytometric analysis of
cleaved caspase-3 (Cell Signaling Technology).
Immunofluorescence assay
3T3 cells stably transfected with myc tagged FIG-ROS(L), FIG-
ROS(S), or empty vector were subjected to immunofluorescence
assay according to protocol (Cell Signaling Technology).
PCR Assay
For RT-PCR, first-strand cDNA was synthesized from 2.5 ug of
total RNA with the use of SuperScript
TM III first-strand synthesis
system (Invitrogen) with oligo (dT)20. Then, the FIG-ROS fusion
gene was amplified with the use of primer pairs FIG-F2 and ROS-
GSP3.1. Wild type FIG and ROS gene was amplified with the use
of primer pairs FIG-F3 and FIG-R8, ROS-Ex31F and ROS-
GSP2, respectively. For genomic PCR, amplification of the fusion
gene was performed with the use of LongRange PCR kit (Qiagen)
Activated Tyrosine Kinases in Cholangiocarcinoma
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and ROS-GSP4.1 for TC03 and U118MG.
Primers
The following primers were used:
ROS-GSP1: 59ACCCTTCTCGGTTCTTCGTTTCCA
ROS-GSP2: 59TCTGGCGAGTCCAAAGTCTCCAAT
ROS-GSP3.1: 59CAGCAAGAGACGCAGAGTCAGTTT
FIG-F2: 59ACTGGTCAAAGTGCTGACTCTGGT
FIG-F3: 59TTGGATAAGGAACTGGCAGGAAGG
FIG-R8: 59ACCGTCATCTAGCGGAGTTTCACT
ROS-Ex31F: 59AGCCAAGGTCCTGCTTATGTCTGT
FIG-F7: 59 TGTGGCTCCTGAAGTGGATTCTGA
ROS-GSP4.1: 59GCAGCTCAGCCAACTCTTTGTCTT
GAPDH-F: 59TGGAAATCCCATCACcCATCT
GAPDH-R: 59GTCTTCTGGGTGGCAGTGAT
Constructs
The open reading frame of the FIG-ROS(L) and FIG-ROS(S)
fusion gene was amplified by PCR from cDNA of ROS fusion
positive patient tumors. These PCR products were cloned into the
retroviral vector MSCV-Neo with a C-terminal Myc tag.
Western blotting
Cells were lysed in 16 cell lysis buffer (Cell Signaling
Technology) supplemented with Protease Arrest
TM (G Biosciences)
and separated by electrophoresis. All antibodies and reagents for
immunoblotting were from Cell Signaling Technology.
Soft agar assay and Xenograft
Retroviral transduced 3T3 cells were selected for G418
(0.5 mg/ml) for 7 days, and the cells were then cultured in soft
agar in triplicate for 17 days. 1610
6 transduced 3T3 cells were
resuspended in Matrigel (BD Biosciences) and injected subcuta-
neously at 2 sites into each nude mice. Each cell line was tested in
4 mice with a total of 8 injections. Mice were monitored daily for
tumor formation and size, and were sacrificed when tumors
reached approximately 1 cm61 cm.
Approval for the use of animals in this study was granted by Cell
Signaling Technology Animal Care and Use Committee with
approval ID 650.
In vitro kinase assay
Cell lysates from FIG-ROS transfected BaF3 cells were
subjected to immunoprecipitation with Myc-Tag antibody, ROS
immune complex were washed 3 times with cell lysis buffer,
followed by kinase buffer (Cell Signaling Technology). Kinase
reactions were initiated by re-suspending the ROS immune
complex into 25 ul kinase buffer that contains 50 uM ATP,
0.2 uCi/ul [gamma32p] ATP, with 1 mg/ml of Poly (EY, 4:1).
Reactions were stopped by spotting reaction cocktail onto p81
filter papers. Samples were then washed and assayed for kinase
activity by detection with a scintillation counter.
Supporting Information
Figure S1 Expression of ROS in primary cholangiocar-
cinoma samples. (A) Detection of ROS expression by Western
blot from protein lysates of a liver cancer patient (TC23). Arrows
denote truncated forms of ROS. (B) Identification of genomic
breakpoints of ROS fusions by sequencing genomic PCR products
from two FIG-ROS positive patients (TC23 and TC03). U118MG
was used as a control.
(TIF)
Figure S2 Expression and characterization of ROS
fusions in either 3T3 cells or BaF3 cells. (A) Expression of
FIG-ROS(L) and FIG-ROS(S) in 3T3 cells phosphorylate their
downstream substrates, such as STAT3 and AKT. Arrow denote
the correct size of FIG-ROS. (B) Expression of SLC34A2-ROS(S)
in either 3T3 or BaF3 cells failed to activate its downstream
signaling molecules. HCC78, which expresses SLC34A2-ROS(S),
was included as a control. (C) Expression of FIG-ROS(L) and
FIG-ROS(S) in BaF3 cells either in the presence of absence of IL3.
(D) BaF3 cells were stably transfected with different ROS fusions,
as well as empty Neo-Myc vector. BaF3 lysates were immunopre-
cipitated with Myc-tag antibody, and kinase assay was performed
as described in experimental procedure. Kinase activity was
expressed relative to that of empty Neo-Myc construct. Western
blot showed similar amount of ROS proteins were used for kinase
reaction.
(TIF)
Table S1 Phosphopeptides identified by LC-MS/MS in cho-
langiocarcinoma patient samples, as well as matching para-tumor
samples. ‘y’ for phosphorylated tyrosine residue; ‘Y’ for unpho-
sphorylated tyrosine residue.
(DOC)
Table S2 Total number of tyrosine phosphopeptides per protein
identified by LC-MS/MS in cholangiocarcinoma patient samples,
which is normalized against the number of total peptides from
GSK3A (set to 100).
(DOC)
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